7:45 AM ET
8-K
Clinical Trial Data
Cerenome Clinical Trial Data
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
- Counterparty
- Society for Neuro-Oncology